Letters to the Editor; If Found Suitable, They Will Be Published As Space Allows

Total Page:16

File Type:pdf, Size:1020Kb

Letters to the Editor; If Found Suitable, They Will Be Published As Space Allows Letters to R eferences 1. Geyman JP, Brown TC, Rivers K Referrals in fam ily practice: A Compaq five study by geographic region and the Editor practice setting. J Fam Pract 3:163,1975 2 . Slabaugh RC, Ringiewicz M, Babi- neau RA: The hospital work at a family practice group in a medium sized com­ munity in New England. J Fam Pract 1V 287, 1980 The Journal welcomes Letters to the Editor; if found suitable, they will be published as space allows. Letters should be typed double-spaced, should not exceed 400 words, and are subject to abridgment and other editorial changes in accordance with journal style. Use of the Family APGAR To the Editor: Over the past four years, Smilk- stein et al have published several articles13 in the Journal o f Family Practice concerning the validity and reliability of the Family The Consultation Note both the patient’s outpatient and APGAR questionnaire as a meas­ hospitalized care. A consultation ure of family function. The ques­ To the Editor: note should therefore be consid­ tionnaire was designed to measure Family physicians provide the ered one of the key elements in a a family member's satisfaction with major portion of the primary care successful consultation. five empirical components of fam­ for their patients. Studies have The consultation note should ily function. Since the publication shown that family physicians han­ include (1) a brief statement of the of their first paper in 1978, Smilk- dle 95 to 98 percent of the definitive problem and reason for the consul­ stein et al have attempted to vali­ care for their patients in the office.1 tation, (2) a master problem list to date the instrument by administer­ Similarly, family physicians main­ put the present illness into per­ ing it to married university stu­ tain a large portion of the direct spective for the consultation, (3) dents, adult community mental care for their hospitalized patients. history and physical findings that health patients, college students in In the hospital setting, however, pertain to the present consultation, an introductory psychology course, the consultation or referral rate is (4) laboratory and x-ray findings, adults in a university psychiatric much higher.2 The total care of the current and attempted therapies, clinic, Taiwanese students aged 10 family cannot be met by any single (5) specific questions the family to 13 years, and last, new patients physician. When more specialized physician wants answered, (6) a in a university family medical care is needed, the continuum of statement specifying the level of practice. care naturally extends into the care desired of the consultant, ie, I applaud the efforts of Dr. arena of consultation and referral. consultation vs referral, and (7) a Smilkstein and colleagues. The de­ The consultation process breaks statement requesting follow-up. velopment of an instrument for the down when open communication is The consultation note is not so rapid screening of family function not maintained. If this occurs, con­ radical an idea as it may first is beneficial to both practitioners tinuity of care is lost, and the appear. Although it requires more and researchers interested in family patient is the one who ultimately time on the part of the family phy­ epidemiology and health care utili­ suffers. sician to formulate and write, the zation. At the Duke University A written consultation note or benefits of providing optimal con­ Family Medicine Center, a similar form better defines the patient’s sultant care for the patient are sure­ instrument has been developed problems, workups done, reasons ly worth it. over the past two years. Different for consultation, and goals of the Joseph E. Ross, MD family characteristics have been consultation. This form should Office for Family Practice empirically chosen for our ques­ improve communication and better Rockford School of Medicine tionnaire based on our reading of delineate the consultant's role in Rockford, Illinois the social science and family therapy 882 THE JOURNAL OF FAMILY PRACTICE, VOL. 16, NO. 5, 1983 LETTERS TO THE EDITOR literature. I have administered the comparison is not valid because respond to Dr. Hoffman’s letter in questionnaire to 154 individuals different facets of a patient’s well­ which he questioned the efficacy of from 128 separate families. I have being are measured in each study the Family APGAR in identifying not used the same criteria as and that the study populations are psychosocial problems. In this Smilkstein to validate this instru­ not comparable. connection I would like to make the ment, but a comparison of my initial I am concerned, however, that following comments: findings with those of Smilkstein the Family APGAR questionnaire 1. The Family APGAR is a serves to highlight problems facing may be relatively insensitive, lead­ screening instrument for family investigators of family function. ing to falsely labeling sick families function. The questionnaire consists of 13 as well families. This is important 2. One cannot always equate the questions with the total score rang­ because physicians who are sensi­ level of family function with the ing from 0 to 100. Equal to or below tive to family problems may easily psychosocial status of the patient. 62 was empirically defined as a identify patients with highly dys­ A patient with family dysfunction sick or poorly functioning family. functional families. But a family will almost invariably manifest Twenty-four percent of the inter­ function questionnaire, if it is to be psychosocial problems; however, viewees in my study scored in the valuable, must entice patients who patients with psychosocial prob­ poorly functioning category. In two otherwise would discuss with their lems may not have family dysfunc­ articles recently published in the physician only somatic complaints tion. Psychosocial problems result Journal,4-5 the percentage of pa­ to reveal dissatisfaction with their from stressful life events that are tients with psychosocial diagnoses family and its functioning. By ask­ not buffered or modified by a pa­ in family practices in Sacramento ing only five broad questions, the tient’s resources (primarily family, and Canada ranged from 30.5 to Family APGAR may too easily friends, and groups). Thus one or 33.3 percent. By comparison, the permit a patient to deny family more overwhelming stressful life distribution of Family APGAR problems. events may cause psychosocial problems even with satisfactory scores achieved by patients in the Richard E. Hoffman, MD university family practice showed School of Hygiene and family function. 15.3 percent scored less than 7 out Public Health 3. The goal of the Family APGAR questionnaire is to help of a total possible score of 10; these Johns Hopkins University respondents were considered to Baltimore, Maryland the physician in assessing whether have moderately to highly dysfunc­ the family is the source of the pa­ References tient’s psychosocial problem or a tional families. The authors3 noted 1. Smilkstein G: The Family APGAR: resource in time of trouble. the bunching of responders at high A proposal for a family function test and Gabriel Smilkstein, MD scores and stated that this ampli­ its use by physicians. J Fam Pract 6:1231, 1978 Department of Family Medicine fied the worth of the Family 2. DelVecchio Good MJ, Smilkstein G, University of Washington APGAR as a screen for patients Good BJ, et al: The Family APGAR index: Seattle, Washington who perceive their family to be A study of construct validity. J Fam Pract 8:577, 1979 dysfunctional. 3. Smilkstein G, Ashworth C, Mon­ At Duke, we have noted that in­ tano D: Validity and reliability of the Fam­ Alcoholism in Family Practice terviewees not uncommonly deny ily APGAR as a test of family function. J Fam Pract 15:303, 1982 family problems and give socially To the Editor: 4. Brennan M, Noce A: A study of pa­ The September 1982 article by desirable responses to our family tients with psychosocial problems in a C. Richard Kirkwood et al on the function questionnaire, thereby fam ily practice. J Fam Pract 13:837, 1981 5. Stumbo D, DelVecchio Good MJ, 50 most common diagnoses in Pa­ falsely elevating their scores. It is Good BJ: Diagnostic profile of a family cific Northwest family practices not clear why the Family APGAR practice clinic: Patients with psychosocial provides a ranked list of these 50 appears to identify a smaller per­ diagnoses. J Fam Pract 14:281, 1982 diagnoses (The diagnostic content centage of poorly functioning fami­ of family practice: 50 most com­ lies in a family practice than in my The preceding letter was referred mon diagnoses recorded in the study or the percentage of persons to Dr. Smilkstein, who responds as WAMI community practices. J with psychosocial diagnoses in the follows: Fam Pract 15:485, 1982). I find it Sacramento and Canadian prac­ distressing, although predictable, tices. Two explanations are that the I appreciate the opportunity to 883 the j o u r n a l o f f a m il y PRACTICE, VOL. 16, NO. 5, 1983 Mazanor® (mazindol) e Wyeth LETTERS TO THE EDITOR Actions— Average magnitude of increased weight loss »fdnn placebo-treated patients in studies of anorectics in genera v narily only a fraction of a pound a week Rate of weight to,, , that alcohol (3031) is not even in ber 1982, present to its parent or­ est in first weeks for both drug and placebo and tends to Z * the top 50, much less in the top five succeeding weeks. Total impact of drug-induced weight i n a Z i’ ganizations a core curriculum on of diet alone must be considered clinically limited * or ten, where it belongs. It is naive occupational medicine for family Indication— Management of exogenous obesity as short termn weeks) adjunct in regimen of weight reduction based on cata to hope that alcoholism is being practice residency programs.
Recommended publications
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • Aminothiazolones As Estrogen Related
    (19) TZZ ¥__T (11) EP 2 536 716 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 417/06 (2006.01) C07D 417/14 (2006.01) 21.05.2014 Bulletin 2014/21 A61K 31/427 (2006.01) A61P 5/30 (2006.01) (21) Application number: 11705404.9 (86) International application number: PCT/US2011/024999 (22) Date of filing: 16.02.2011 (87) International publication number: WO 2011/103130 (25.08.2011 Gazette 2011/34) (54) AMINOTHIAZOLONES AS ESTROGEN RELATED RECEPTOR-ALPHA MODULATORS AMINOTHIAZOLONE ALS ERR-ALPHA-MODULATOREN AMINOTHIAZOLONES EN TANT QUE MODULATEURS DE RÉCEPTEUR ALPHA ASSOCIÉ AUX STROGÈNES (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • BIGNAN, Gilles GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Spring House, PA 19477 (US) PL PT RO RS SE SI SK SM TR • GAUL, Micheal Designated Extension States: Spring House, PA 19477 (US) BA ME • XU, Guozhang Spring House, PA 19477 (US) (30) Priority: 17.02.2010 US 305177 P •ZHAO,Bao- ping Spring House, PA 19477 (US) (43) Date of publication of application: 26.12.2012 Bulletin 2012/52 (74) Representative: Carpmaels & Ransford LLP One Southampton Row (73) Proprietor: Janssen Pharmaceutica, N.V. London WC1B 5HA (GB) 2340 Beerse (BE) (56) References cited: WO-A1-2008/109737 Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Toxicology Solutions
    Toxicology Solutions Contents Biochip Array Technology Overview 04 Benefits 05 Testing Process 06 The Evidence Series 08 Evidence+ 10 Evidence 12 Evidence Investigator 14 Evidence MultiSTAT 16 Matrices 18 Test Menu 20 Customisable Test Menu 24 Catalogue Numbers 26 ELISA 28 Cross Reactivity 30 Technical Support 37 Ordering Information 38 Introduction Randox Toxicology aim to minimise laboratory workflow constraints whilst maximising the scope of quality drug detection. We are the primary manufacturer of Biochip Array Technology, ELISAs, and automated systems for forensic, clinical and workplace toxicology. Biochip Array Technology Moving away from traditional single analyte assays, Biochip Array Technology (BAT) boasts cutting-edge multiplex testing capabilities providing rapid and accurate drug detection from a single sample. Based on ELISA principles, the Biochip is a solid state device with discrete test regions onto which antibodies, specific to different drug compounds, are immobilised and stabilised. Competitive chemiluminescent immunoassays are then employed, offering a highly sensitive screen. Designed to work across a wide variety of matrices, this revolutionary multi- analyte testing platform allows toxicologists to achieve a complete immunoassay profile from the initial screening phase. Offering the most advanced screening technology on the market, Randox Toxicology has transformed the landscape of drugs of abuse (DoA) testing. Our unrivalled toxicology test menu is capable of detecting over 500 drugs and drug metabolites. 4 Benefits Simultaneous detection Multiplex testing facilitates simultaneous screening of various drugs and drug metabolites from a single sample. Accurate testing Biochip Array Technology has a proven high standard of accurate test results with CVs typically <10%. Small sample volume As little as 6μl of sample produces a complete immunoassay profile, leaving more for confirmatory testing.
    [Show full text]
  • Monoamine Reuptake Inhibitors in Parkinson's Disease
    Hindawi Publishing Corporation Parkinson’s Disease Volume 2015, Article ID 609428, 71 pages http://dx.doi.org/10.1155/2015/609428 Review Article Monoamine Reuptake Inhibitors in Parkinson’s Disease Philippe Huot,1,2,3 Susan H. Fox,1,2 and Jonathan M. Brotchie1 1 Toronto Western Research Institute, Toronto Western Hospital, University Health Network, 399 Bathurst Street, Toronto, ON, Canada M5T 2S8 2Division of Neurology, Movement Disorder Clinic, Toronto Western Hospital, University Health Network, University of Toronto, 399BathurstStreet,Toronto,ON,CanadaM5T2S8 3Department of Pharmacology and Division of Neurology, Faculty of Medicine, UniversitedeMontr´ eal´ and Centre Hospitalier de l’UniversitedeMontr´ eal,´ Montreal,´ QC, Canada Correspondence should be addressed to Jonathan M. Brotchie; [email protected] Received 19 September 2014; Accepted 26 December 2014 Academic Editor: Maral M. Mouradian Copyright © 2015 Philippe Huot et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The motor manifestations of Parkinson’s disease (PD) are secondary to a dopamine deficiency in the striatum. However, the degenerative process in PD is not limited to the dopaminergic system and also affects serotonergic and noradrenergic neurons. Because they can increase monoamine levels throughout the brain, monoamine reuptake inhibitors (MAUIs) represent potential therapeutic agents in PD. However, they are seldom used in clinical practice other than as antidepressants and wake-promoting agents. This review article summarises all of the available literature on use of 50 MAUIs in PD. The compounds are divided according to their relative potency for each of the monoamine transporters.
    [Show full text]
  • Comparison of the Effects of Venlafaxine, Paroxetine and Desipramine on the Pupillary Light Reflex in Man
    Psychopharmacology (1999) 143 : 286–292 © Springer-Verlag 1999 ORIGINAL INVESTIGATION P. Bitsios · E. Szabadi · C.M. Bradshaw Comparison of the effects of venlafaxine, paroxetine and desipramine on the pupillary light reflex in man Received: 29 July 1998/Final version: 17 November 1998 Abstract Rationale: The time-course of the pupillary effects. Conclusions: The increase in resting pupil diam- light reflex response is determined by the successive eter could be indicative of parasympathetic inhibition activation of the parasympathetic and sympathetic and/or sympathetic activation. The shortening of the innervations of the iris, the latency and the amplitude recovery time of the light reflex response is consistent reflecting parasympathetic and the recovery time with sympathetic potentiation resulting from nora- mainly sympathetic activity. Objective: To compare the drenaline uptake blockade in the iris. The prolonga- effects of single doses of three antidepressants (ven- tion of the latency and decrease of the amplitude of lafaxine: serotonin/noradrenaline reuptake inhibitor, the light reflex response are indicative of a parasym- paroxetine: selective serotonin reuptake inhibitor, and patholytic effect of venlafaxine. However, as venlafax- desipramine: tricyclic antidepressant) on resting pupil ine has negligible affinity for muscarinic cholinoceptors, diameter and the pupillary light reflex response. this effect cannot be attributed to the blockade of Methods: Fifteen healthy male volunteers participated cholinoceptors in the iris. A possible explanation for in five weekly sessions, each of which was associated this finding is that it reflects a central rather than a with one treatment (venlafaxine 75 mg or 150 mg, peripheral effect of the drug: the blockade of nora- paroxetine 20 mg, desipramine 100 mg, or placebo) drenaline uptake in the brain could lead to the poten- according to a double-blind, double-dummy, balanced, tiation of the noradrenergic inhibition of central cross-over design.
    [Show full text]
  • 2012 Harmonized Tariff Schedule Pharmaceuticals Appendix
    Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2014) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEVALTRATE 25161-41-5 ABAFUNGIN 129639-79-8 ACEXAMIC ACID 57-08-9 ABAGOVOMAB 792921-10-9 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACLIDINIUM BROMIDE 320345-99-1 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURIN 178535-93-8 ACOLBIFENE 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDE 185106-16-5
    [Show full text]
  • Lactose Intolerance and Health: Evidence Report/Technology Assessment, No
    Evidence Report/Technology Assessment Number 192 Lactose Intolerance and Health Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road Rockville, MD 20850 www.ahrq.gov Contract No. HHSA 290-2007-10064-I Prepared by: Minnesota Evidence-based Practice Center, Minneapolis, MN Investigators Timothy J. Wilt, M.D., M.P.H. Aasma Shaukat, M.D., M.P.H. Tatyana Shamliyan, M.D., M.S. Brent C. Taylor, Ph.D., M.P.H. Roderick MacDonald, M.S. James Tacklind, B.S. Indulis Rutks, B.S. Sarah Jane Schwarzenberg, M.D. Robert L. Kane, M.D. Michael Levitt, M.D. AHRQ Publication No. 10-E004 February 2010 This report is based on research conducted by the Minnesota Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA 290-2007-10064-I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services. The information in this report is intended to help clinicians, employers, policymakers, and others make informed decisions about the provision of health care services. This report is intended as a reference and not as a substitute for clinical judgment. This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies.
    [Show full text]
  • Mazindol Treatment of Negative Symptoms William T
    Mazindol Treatment of Negative Symptoms William T. Carpenter, Jr., M.D., Alan Breier, M.D., Robert W. Buchanan, M.D., Brian Kirkpatrick, M.D., Paul Shepard, Ph.D., and Elaine Weiner, M.D. Hypodopaminergic and hyponoradrenergic pathophysiology subjects were similar, and were not affected by whether may be a basis for primary and/or secondary negative concurrent the antipsychotic drug treatment was clozapine, symptoms in schizophrenia. The hypothesis that enhanced fluphenazine, or haloperidol. The efficacy hypothesis was neurotransmission in these systems would be therapeutic not supported for either primary or secondary negative for negative symptoms was tested by comparing mazindol symptoms. [Neuropsychopharmacology 23:365–374, and placebo in a double-blind, cross-over design trial. 2000] © 2000 American College of Outcome following mazindol supplementation was Neuropsychopharmacology. Published by Elsevier comparable to placebo supplementation (F(1,30) ϭ 0.9; p ϭ Science Inc. .57). Results for deficit and non-deficit schizophrenia KEY WORDS: Schizophrenia; Mazindol; Negative symptoms; Negative symptoms of schizophrenia are defined Clinical trial; Dopamine more broadly than anhedonia, but the core features of reduced social drive, restricted emotional experience Many mental and physical states can temporarily re- and expression, alogia, and a diminished capacity for duce an individual’s ability to experience pleasure, the experience of pleasure are hypothesized to emerge gratification, and reinforcement. However, when Rado from pathophysiology in the neural circuits concerned (1956) described anhedonia as a core feature of schizo- with drive, emotion, and reward. Dopaminergic and phrenia, he referred to an enduring or trait reduction in noradrenergic neurons are central to the mediation of capacity rather than a transitory or state impairment.
    [Show full text]
  • Lobelane Analogs with Various Methylene Linker Lengths and Acyclic Lobelane Analogs As Potential Pharmacotherapies to Treat Methamphetamine Abuse
    University of Kentucky UKnowledge Theses and Dissertations--Pharmacy College of Pharmacy 2014 LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE Zheng Cao University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits ou.y Recommended Citation Cao, Zheng, "LOBELANE ANALOGS WITH VARIOUS METHYLENE LINKER LENGTHS AND ACYCLIC LOBELANE ANALOGS AS POTENTIAL PHARMACOTHERAPIES TO TREAT METHAMPHETAMINE ABUSE" (2014). Theses and Dissertations--Pharmacy. 32. https://uknowledge.uky.edu/pharmacy_etds/32 This Doctoral Dissertation is brought to you for free and open access by the College of Pharmacy at UKnowledge. It has been accepted for inclusion in Theses and Dissertations--Pharmacy by an authorized administrator of UKnowledge. For more information, please contact [email protected]. STUDENT AGREEMENT: I represent that my thesis or dissertation and abstract are my original work. Proper attribution has been given to all outside sources. I understand that I am solely responsible for obtaining any needed copyright permissions. I have obtained needed written permission statement(s) from the owner(s) of each third-party copyrighted matter to be included in my work, allowing electronic distribution (if such use is not permitted by the fair use doctrine) which will be submitted to UKnowledge as Additional File. I hereby grant to The University of Kentucky and its agents the irrevocable, non-exclusive, and royalty-free license to archive and make accessible my work in whole or in part in all forms of media, now or hereafter known.
    [Show full text]
  • PRODUCT MONOGRAPH SANOREX® Mazindol 1 and 2 Mg Tablets
    PRODUCT MONOGRAPH Pr SANOREX® Mazindol 1 and 2 mg tablets Anorexiant HEXIM Pharmaceuticals Inc. Date of Preparation: 600 Meadowlands Parkway, Suite 149 July 7, 2015 Secaucus, New Jersey, USA 07094 Control # 185010 ® - Registered trademark of Novartis Pharmaceuticals Canada Inc. HEXIM Pharmaceuticals Inc. licensed user 2 PRODUCT MONOGRAPH Pr SANOREX® Mazindol 1 and 2 mg tablets THERAPEUTIC CLASSIFICATION Anorexiant ACTIONS AND CLINICAL PHARMACOLOGY SANOREX® (mazindol) is an imidazo-iso-indole anorectic agent which shares many pharmacological properties with the amphetamines and their congeners. The effects of mazindol include central nervous system stimulation as well as an anorectic action. It has not been established, however, that the action of such drugs in treating obesity is exclusively one of appetite suppression. Other central nervous system actions or 3 metabolic effects may be involved as well. As with similar drugs, rebound weight gain may occur after discontinuation of mazindol. Tolerance to the anorectic action has been demonstrated with all drugs of this class in which this phenomenon has been studied. Absorption of mazindol occurs with a half life of 1 hour. A single oral dose of 1 or 2 mg can be identified in the blood after 30 minutes. Maximum plasma concentrations are attained on average after 3.6 hours. Plasma protein binding is 77%. The elimination half life in plasma is approximately 10 hours. Urinary excretion of unchanged substance and metabolites amounts to 40 to 50%, of which about 4% represents unchanged substance. INDICATIONS AND CLINICAL USE As a short-term (i.e. a few weeks) adjunct to continued dietary treatment in the medical management of obesity, in patients who have not responded to an appropriate weight reducing diet alone.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • A New Weight-Reducing Drug with Novel Properties DAVID WHEATLEY M.D., F.R.C.Psych
    Postgrad Med J: first published as 10.1136/pgmj.58.679.279 on 1 May 1982. Downloaded from Postgraduate Medical Journal (May 1982) 58, 279-281 A new weight-reducing drug with novel properties DAVID WHEATLEY M.D., F.R.C.Psych. The General Practitioner Research Group, 325 Staines Road, Twickenham, U.K. Summary (1980) compared ciclazindol to placebo over a 3- Ciclazindol, a tetracyclic compound originally de- week treatment period following a 2-week control veloped as an antidepressant, was compared to placebo period. During treatment, patients on ciclazindol in a double-blind trial involving 114 individuals who lost significantly more weight than those on placebo, were at least 15 % overweight. Following a one week but this was not maintained during the third week of control period patients were allocated to active or the trial. placebo groups by random distribution for a period of 4 weeks and this was followed by a final one-week Method observation period. Ciclazindol, in a dose of 25-50 mg daily, was The mean weight loss of 47 patients who completed compared to placebo under double-blind conditions, the trial on ciclazindol was 6 95 lbs (3-13 kg) and of patients being treated for 4 weeks with one or the 48 patients who completed the trial on placebo it was other according to random selection, following a 5 0 lbs (2 25 kg) a difference which is statistically one-week control period with no treatment. There copyright. significant in favour of ciclazindol (P< 0 05). was also a final one-week follow-up, again with no The trial demonstrated a marked placebo effect treatment.
    [Show full text]